Age-Related Macular Degeneration (AMD) Market Trends & Summary

Introduction

The Age-Related Macular Degeneration (AMD) Market is on track to reach US$ 20.88 billion by 2033, rising from US$ 11.42 billion in 2024, and expanding at a CAGR of 6.94% from 2025 to 2033, according to Renub Research. The accelerating burden of AMD worldwide—driven by aging demographics, lifestyle-associated risks, advances in screening, and rapid innovation in ophthalmic therapeutics—is reshaping global eye-care markets.

AMD remains one of the most common and devastating causes of irreversible blindness among people aged 60 and older. With longer life expectancy across developed and emerging economies, demand for timely diagnosis, affordable treatment, and improved long-term management solutions continues to climb.

The Age-Related Macular Degeneration (AMD) Global Market & Forecast 2025–2033 report covers:

Disease Type: Dry AMD & Wet AMD

Product: Eylea, Lucentis, Beovu & Others

Distribution Channels: Hospital Pharmacy, Specialty Pharma & Online Pharmacy

Regions: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa

Company Profiling & Analysis: Bayer AG, GSK, Novartis, Roche, AbbVie, Regeneron, Bausch Health, and more.

Global Age-Related Macular Degeneration (AMD) Industry Overview

AMD is the leading cause of blindness in industrialized nations, particularly among older adults. It progressively damages the macula—the central part of the retina responsible for sharp vision—affecting daily activities such as reading, color distinction, facial recognition, and driving. As the disease advances, central vision becomes distorted or lost entirely.

AMD progresses across three primary stages:

Early Stage: Presence of drusen and pigment irregularities

Intermediate Stage: Increased drusen, RPE changes

Late Stage: Wet AMD (neovascular) or Dry AMD (geographic atrophy)

Over time, AMD is further categorized into:

Dry (Atrophic) AMD: The most common form, progressing slowly

Wet (Neovascular) AMD: Less common but responsible for 90% of severe vision loss

Despite decades of research, the exact pathological mechanism of AMD remains unclear. However, advancements in genetic testing and biomarker discovery have identified key variants with significant implications for disease classification and personalized therapies.

Aging remains the strongest risk factor. According to the Population Reference Bureau, the U.S. population aged 65+ will increase by 47% between 2022 and 2050, reaching 82 million—creating an unprecedented expansion in the AMD patient pool.

In North America alone, 200,000 new wet AMD cases emerge annually, highlighting the urgent need for scalable care, early detection, and cost-effective treatments.

Request Free Sample Report

Market Growth Drivers

1. Innovative Treatment Options

The AMD treatment landscape has transformed significantly with the development of anti-VEGF (vascular endothelial growth factor) therapies, including Eylea, Lucentis, and Beovu. These injections inhibit abnormal blood vessel growth and leakage in the retina, helping stabilize or even improve vision in a substantial share of wet AMD cases.

Key innovation trends fueling market expansion include:

Next-generation anti-VEGF agents offering extended dosing intervals

Biosimilars reducing treatment costs and improving accessibility

Gene therapies targeting the root cause of neovascularization

Stem-cell-based regenerative treatments for early-stage AMD

Long-acting drug delivery implants reducing treatment burden

As pipelines expand and clinical research intensifies, more therapeutic candidates are set to enter the market, broadening patient choices and improving long-term outcomes.

2. Increasing Awareness & Early Screening

Rising global awareness—driven by healthcare providers, NGOs, and vision advocacy groups—is a major catalyst for early detection and intervention. Public health campaigns focusing on:

Early symptom recognition

Lifestyle risk factor modification

Regular eye exams after age 50

Access to retina specialists

have significantly improved diagnosis rates.

Improved awareness is especially impactful in developing nations, where historically, AMD has gone undetected until vision loss becomes irreversible. As screening becomes more accessible, demand for both diagnostics and therapeutics continues to grow.

3. Rising Healthcare Investments

Ophthalmology has emerged as a critical focus area for private, public, and venture-capital investment. The direct impact of vision loss on quality of life, productivity, and healthcare expenditure has made AMD a high-priority therapeutic category.

Growing investments contribute to:

New molecule discoveries

Next-gen retinal imaging technologies

Availability of advanced diagnostics in emerging markets

AI-driven early detection tools

Large-scale Phase II & III clinical trials

These investments collectively accelerate innovation and expand global treatment reach, fostering overall market growth.

Market Challenges

1. High Treatment Costs

AMD therapies—particularly anti-VEGF injections—are some of the most expensive long-term chronic treatments worldwide. Wet AMD patients often require:

Monthly or bi-monthly injections

Frequent OCT scans

Lifetime follow-up

In low- and middle-income economies, the cost burden severely restricts access. Even in developed markets, reimbursement limitations force many patients to discontinue therapy prematurely. This creates long-term socioeconomic impacts due to preventable blindness.

2. Lack of Early Diagnosis

AMD often progresses without symptoms in its initial stages. Many individuals seek medical assistance only after substantial vision loss. Limited access to routine eye exams, especially in older adults, further worsens diagnostic delays.

Key limitations include:

Undiagnosed early-stage AMD

Misdiagnosis in general ophthalmology settings

Insufficient rural healthcare access

Patient presentation only at advanced stages

Delayed diagnosis significantly reduces treatment efficacy, particularly for wet AMD, where early intervention is critical.

Regional Market Analysis

United States

The U.S. AMD market is expanding rapidly due to:

High aging population

Early adoption of new retinal therapies

Advanced diagnostic infrastructure

Favorable reimbursement for anti-VEGF treatments

Challenges include high treatment cost and limited options for dry AMD. However, strong R&D pipelines and active clinical trial participation keep the U.S. at the forefront of innovation.

Germany

Germany remains a leading European AMD market, supported by:

A robust national healthcare system

High public awareness of eye health

Widespread access to proven anti-VEGF therapies

Strong presence of global pharmaceutical companies

Challenges include high spending per patient and limited treatment options for geographic atrophy. Regulatory frameworks and reimbursement policies also shape treatment accessibility.

India

India’s AMD market is driven by:

A rapidly growing elderly population

Increased urban awareness

Rising adoption of anti-VEGF therapies

However, major challenges persist:

Limited access in rural regions

High cost of treatment

Lack of early screening

Shortage of retina specialists

Despite these barriers, government health missions and rising demand for affordable ophthalmic care are expected to drive growth.

Saudi Arabia

Saudi Arabia’s AMD market is growing as a result of:

Improving healthcare infrastructure

Increased screening in urban areas

Rising elderly population

Greater awareness about early eye-care intervention

Accessibility and affordability remain challenges, particularly in remote regions. However, government investment under Vision 2030 continues to expand advanced diagnostic and treatment facilities, supporting market growth.

Age-Related Macular Degeneration (AMD) Market Segmentation

By Disease Type

Dry AMD

Wet AMD

By Product

Eylea

Lucentis

Beovu

Others

By Distribution Channel

Hospital Pharmacy

Specialty Pharma

Online Pharmacy

By Country Coverage

North America: United States, Canada

Europe: France, Germany, Italy, Spain, UK, Belgium, Netherlands, Turkey

Asia-Pacific: China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, New Zealand

Latin America: Brazil, Mexico, Argentina

Middle East & Africa: South Africa, Saudi Arabia, UAE

Key Players Covered (4 Viewpoints Each)

Overview

Key Persons

Recent Developments & Strategies

Financial Insights

Major Companies

Hoffmann-La Roche Ltd.

Bayer AG

AbbVie

GSK Plc

Novartis AG

Regeneron Pharmaceuticals

Bausch Health Companies Inc.

Alimera Sciences Inc.

Final Thoughts

The Age-Related Macular Degeneration (AMD) market is entering a transformative decade. With a rapidly aging world population, expanding diagnostic capabilities, and breakthrough innovations—from anti-VEGF therapies to gene-based treatments—the industry is poised for substantial growth.

Yet, challenges such as high treatment costs, limited access in emerging economies, and delayed diagnosis continue to shape market dynamics. Opportunities remain massive, especially in Asia-Pacific, where population expansion and rising healthcare spending are accelerating adoption.

As AMD continues to impact millions globally, companies that innovate early, reduce treatment burden, and expand patient accessibility will define the future of global vision care.